Versartis
Inc. (Nasdaq: VSAR) modified its ongoing Phase 3 registration trial of
somavaratan. Shares of the biopharmaceutical plummeted $2.42 to close at
$10.72.
Versartis modifies registration trial
September 15, 2015 at 11:47 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.